International Clinical Trial: Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth:a Non-inferiority Randomized Controlled Study

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815548) titled 'Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth:a Non-inferiority Randomized Controlled Study' on Sept. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shandong University

Condition: Small Intestinal Bacterial Overgrowth Syndrome (SIBO)

Intervention: Drug: Saccharomyces boulardii sachets

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: September 10, 2026

Target Sample ...